Our services span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
Site and patient identification, enrolment and engagement
Integrated services that cover planning, management, execution and analysis.
We have extensive experience in a broad range of therapeutic
areas. Managing studies in all major geographies, we have
established solid working relationships with the world’s
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
ICON has recently led the development of 14 vaccines resulting in FDA/EMA approvals
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Connecting patients with the right trial in the right location
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
Reduce post market study costs with Real World Data
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
Transforming Trials to help bring Cost Effective Medical Devices & Diagnostics to Market
Entering a New Era for Market Access
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
A survey of industry executives
Perspectives from senior pharma executives
Engage assay experts with deep experience and expertise
Making it easier for the site and patient
Primary research evaluating ICER’s influence over payers and manufactures
Develop the right business strategy to successfully navigate MDR/IVDR
Understanding formulary decision maker & manufacturer challenges
Determine the right design, assessments and endpoints in your pain study
According to an ICON survey, artificial intelligence (AI) was
considered the digital technology with the most potential to
improve R&D productivity
Taking into consideration the lessons learned from Alzheimer’s disease studies could benefit the design of neuro-protective studies.
Orphan drugs, by nature, remain commercially underdeveloped, and as
demand in the market increases, patients in clinical trials need to be considered.
Sites participating in ACT trials need to be prepared with
regulatory intelligence, scalable logistics, adequate
resources and dedicated data management teams.
Attempting to develop casual treatment against the progression of
Alzheimer’s disease has resulted in unparalleled series of failures for
nearly 2 decades of drug development.
The size and significance of the APAC market make clinical
trials, on the cutting edge of oncology development, an
As more RWE is generated within the biotech industry, a
strategic plan is necessary to maximise revenue.
As the buzz around voice technology increases, our digital team is
asked more & more, “What’s the deal with voice assistants? Can we
offer this to our clients?”
Various regulatory efforts have been implemented in the last 25-30 years to
include the patients’ perspective into drug development.